NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


Don't have an account? Subscribe

ADVERTISEMENT

ADVERTISEMENT

Almost €800k paid by pharma to unidentified HCPs

By Catherine Reilly - 21st Sep 2021

View on the globe zoomed on Eurozone: Austria, Belgium, Cyprus, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Portugal, Slovakia, Slovenia,Spain, Latvia, including Lithuania (1 -1-2015) in dark blue.

In 2020, pharmaceutical companies provided €1.35 million to Irish healthcare professionals (HCPs) who disclosed their names on the transfer of value (ToV) register operated by the Irish Pharmaceutical Healthcare Association (IPHA). A further €746,322 was provided to HCPs who declined to be named, according to figures supplied to the Medical Independent (MI) by IPHA.

The ToVs to HCPs — mostly doctors — included fees for consultancy/services and related expenses, as well as registration fees for conferences and associated travel/accommodation. The total payments were vastly reduced on previous years, when HCPs received approximately €6 million. IPHA would not speculate on the reasons for the decline, although the pandemic appears to have been one likely factor.

Healthcare organisations, including hospitals and clinical societies, received €7.76 million from pharmaceutical companies in 2020. The payments took the form of donations, grants and event sponsorships, as well as expenses.

According to IPHA, companies invested over €27.5 million in research and development last year, a 33 per cent increase compared with 2019.

IPHA’s spokesperson told MI: “Since July 2016, details of biopharmaceutical companies’ engagements with healthcare practitioners and healthcare organisations have been publicly disclosed. Our industry initiated this move towards greater transparency in financial transactions.”

See news feature Under the microscope: Irish pharma’s engagement with doctors – Medical Independent

Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
Medical Independent 5th March
The Medical Independent 5th March 2024

You need to be logged in to access this content. Please login or sign up using the links below.

ADVERTISEMENT

Most Read

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT